vendredi 22 juin 2012

Press Review (June 23, 2012) – Revue de presse (23 juin 2012)

FDA advisers back Onyx blood cancer drug
U.S. drug advisers backed Onyx Pharmaceuticals Inc's drug (carfilzomib, Kyprolis) for patients who have failed to successfully treat their blood cancer with other medicines, making it likely the drug would secure approval from U.S. regulators.
By Anna Yukhananov. In Reuters

Cancer, a New View: Can You Believe it?
I learned, recently, about the father of a friend who committed suicide because he couldn't handle the painful side effects of radiation and chemo. It's tragic in every sense of the word that someone resolves their cancer but can't live with the agonizing, life-limiting challenges caused by the treatment. I wish there was more publicity given to the hard facts about long-term side effects of conventional cancer treatment. We don't shy away from the fact that there are soldiers who come home from battle only to take their own lives. Why don't we talk more about the casualties of modern-day cancer treatments?.
By Leigh Fortson. In Huffington Post

Could Sunlight Lower Your Odds for Pancreatic Cancer?
Experts say early study results are no reason to tan, however, given UV rays' link to skin cancer.
By Maureen Salamon. In U.S. News & World Report

Smoking Might Raise Your Odds for Skin Cancer
Review of data finds higher risk for squamous cell carcinomas.
In U.S. News & World Report

Study doubts value of liver cancer screening‎
Study doubts value of liver cancer screening‎.
By Amy Norton. In Reuters

Roche's breast cancer drug extends survival in study‎
A late-stage study showed that women with an aggressive type of breast cancer lived significantly longer when treated with Roche's new breast cancer drug Perjeta, the Swiss drugmaker said on Friday..
In Reuters

Darwin’s Principles Say Cancer Will Always Evolve to Resist Treatment
According to researchers at Moffitt Cancer Center, cancer is subject to the evolutionary processes laid out by Charles Darwin in his concept of natural selection. Natural selection was the process identified by Darwin by which nature selects certain physical attributes, or phenotypes, to pass on to offspring to better “fit” the organism to the environment.
In Newswise

Breast Cancer's Many Drivers
Breast cancer is not a single disease, but a collection of diseases with dozens of different mutations that crop up with varying frequency across different breast cancer subtypes. Deeper exploration of the genetic changes that drive breast cancer is revealing new complexity in the leading cause of cancer death in women worldwide.
In Science Daily

Infinity stops two cancer drug trials
Infinity Pharmaceuticals stopped two mid-stage trials of its experimental drug (saridegib) to treat a rare bone marrow disorder and a type of bone cancer, sending the company's shares down 21 percent in premarket trade‎.
In Reuters

New Therapies Show Some Promise Against Pancreatic Cancer
Often resistant to chemo, two treatments might help beat back disease, experts say.
By Amanda Gardner. In U.S. News & World Report

Le travail de nuit des femmes aggrave le risque de cancer du sein‎‎
Le risque de cancer du sein est fortement augmenté chez les femmes ayant travaillé de nuit, selon une étude menée par des chercheurs de l'Institut national de la santé et de la recherche médicale (Inserm) et publiée lundi 18 juin sur le site de la revue International Journal of Cancer. Cette étude confirme d'autres résultats qui ont conduit en 2010 le Centre international de recherche contre le cancer à classer le travail de nuit comme "probablement cancérigène".
Par Paul Benkimoun. Dans Le Monde

Les cabines de bronzage, un risque doublé de cancer de la peau
L’été commence officiellement jeudi 21 juin et comporte son lot de dangers, parmi lesquels une exposition trop importante au soleil. Pour s'en protéger, on peut croire qu'il est pertinent d’utiliser les cabines de bronzage pour préparer sa peau. Malheureusement, elles ne font que multiplier par deux les risques de cancer de la peau, comme l’explique Évelyne Sage, spécialiste des rayonnements ionisants.
Dans Futura-Sciences

Des progrès restent à faire contre la douleur liée aux cancers
Trop "hospitalo-centrée", la gestion de la souffrance doit être simplifiée et davantage confiée aux médecins de ville.
Par Anne Jeanblanc. Dans Le Point

Médicaments: pénurie d'ImmuCyst, utilisé pour certains cancers de la vessie
Une pénurie d'un médicament l'ImmuCyst, utilisé pour certaines formes de cancer de la vessie, liée à des problèmes de production dans une usine canadienne sévit en France, selon des spécialistes et l'agence du médicament qui indique faire tout pour résoudre ce problème.

Trop de thé serait lié au cancer de la prostate
Apparemment, les gros buveurs de thé, soit sept tasses par jour, ont jusqu'à 50% plus de risques de souffrir d'un cancer de la prostate, rapporte le Nutrition and Cancer.
Dans Canoë

Aucun commentaire:

Enregistrer un commentaire